# A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Source: https://onco.cc/trials/nct06919965/  
OnCo record `nct06919965` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing TAR-210 in bladder & urothelial cancer, now recruiting.

## Summary

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer is a phase 3 interventional study registered as NCT06919965, led by Janssen Research & Development, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG). Planned enrolment is 220 participants (estimated). The study started in 2025-09-10 and primary completion is expected in 2028-04-06. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: MoonRISe-3
- Tags: ctgov-ingest
- Registry id: NCT06919965
- Phase: 3
- Setting: A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
- Sponsor: Janssen Research & Development
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT06919965: https://clinicaltrials.gov/study/NCT06919965

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Non-muscle-invasive bladder cancer](https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/)
- drugs: [TAR-210](https://onco.cc/drugs/tar-210/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct06919965.json